COLORADO SPRINGS, CO - (NewMediaWire) - November 30, 2015 - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based formulation, announces the launch of their cannabinoid-formulated capsule product line. The initial capsule formulations released are CBD, Indica, and Sativa; each of the three types of caps will be available in 25mg, 50mg, and 100mg doses and will be provided in two-dose packs with more size options to be made available in the near future.
"We are very excited to get our next line of Cannabis Science Brand Products on the market. The Capsules are important because of the popularity and ease of the delivery mechanism. The Company reps have already begun distributing to a number of dispensaries throughout California. They anticipate the Caps to be in a much larger number of dispensaries, and look forward to being able to line the shelves with a full lineup of Cannabis Science Brand Health-Related Products. Debuting the Caps at the Emerald Cup will be very interesting for us, with this being our first actual product contest," stated Cannabis Science, Inc. President & CEO, Co-Founder, Raymond C. Dabney.
Just in time for the Emerald Cup event in Santa Rosa, California, on December 12th and 13th, 2015. Cannabis Science will be prepared to debut their new, high potency CBD, Indica, and Sativa capsules at the event. The capsules or "caps" are expected be used for self-medicating applications ranging from pain and inflammation reduction to neurological treatments. The Emerald Cup event is expected to expose Cannabis Science's new products to a wide audience immediately, which will help the company build brand equity in this relatively new market.
Mr. Dabney concludes, "It has certainly been a long road to get here, but we are here no doubt. To see things coming together as they are, is very exciting for us of course. With the dividend almost completed, more new products being released, preparations for the larger capital raise, progressing our formal FDA drug development initiatives and proposed NASDAQ uplisting, things are certainly on the move, in the right direction. On the dividend, we have submitted some additional requested documentation to FINRA; we hope this to be the last and then we can begin the dividend share distribution and proceed to file for a new additional trading symbol to accommodate the much larger capital raise."
About The Emerald Cup
The Emerald Cup is a cannabis-centered festival and competition promoting the growth and use of natural, ethically, sun-grown cannabis. It will feature a multitude of vendors, speakers, artists, dispensaries, and collectives and will be held in Santa Rosa, California on December 12th and 13th, 2015.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.